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Abstract
Access and adherence to antiretroviral therapy (ART) has transformed the face of HIV
infection from a fatal to a chronic disease. However, ART is also known for its side effects.
Studies have reported that ART is associated with depressive symptomatology. Large-scale
HIV clinical databases with individuals’ longitudinal depression records, ART medications,
and clinical characteristics offer researchers unprecedented opportunities to study the ef-
fects of ART drugs on depression over time. We develop BAGEL, a Bayesian graphical
model to investigate longitudinal effects of ART drugs on a range of depressive symp-
toms while adjusting for participants’ demographic, behavior, and clinical characteristics,
and taking into account the heterogeneous population through a Bayesian nonparametric
prior. We evaluate BAGEL through simulation studies. Application to a dataset from the
1
ar
X
iv
:2
00
7.
01
48
4v
1 
 [s
tat
.M
E]
  3
 Ju
l 2
02
0
Women’s Interagency HIV Study yields interpretable and clinically useful results. BAGEL
not only can improve our understanding of ART drugs effects on disparate depression symp-
toms, but also has clinical utility in guiding informed and effective treatment selection to
facilitate precision medicine in HIV.
KEY WORDS: Bayesian nonparametrics, Depression, Graphical model, Longitudinal
cohort study, Precision medicine.
1 Introduction
Antiretroviral therapy (ART) has transformed HIV into a manageable, chronic illness despite
its known central nervous system (CNS) side effects, which can complicate disease management.
Some of the most commonly reported ART-related CNS adverse effects include depression and
anxiety, suicidal ideation, developmental disorders, and neurological toxicities (Nanni et al., 2015;
Zash et al., 2018). The presence of these CNS symptoms is a major public health concern as they
are associated with ART discontinuation and increases in the likelihood of HIV transmission.
Therefore, a major component of care for people living with HIV includes management and
prevention of the long-term adverse effects of ART. In this paper, we focus on ART-related effects
on depressive symptomatology. Depression is one of the leading mental health comorbidities in
people with HIV (Bengtson et al., 2016), and is associated with poor ART adherence, HIV disease
progression, and engagement in risky taking behaviors (Chattopadhyay et al., 2017; Ironson
et al., 2017; Brickman et al., 2017). The high prevalence and harmful effects of depression among
people with HIV highlight the need of effective clinical management and adequate treatment for
depression.
At present, there are more than 30 U.S. Food and Drug Administration-approved ART drugs
to treat people with HIV or at risk for HIV. Common ART drugs fall into five drug classes,
including nucleotide reverse transcriptase inhibitor (NRTI), non-nucleotide reverse transcriptase
inhibitor (NNRTI), protease inhibitor (PI), entry inhibitor (EI), and integrase inhibitor (INSTI).
Although ART may alleviate depressive symptoms through suppressing viral load and improving
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physical health for people with HIV, ART can also exacerbate depressive symptoms through
several possible mechanisms, including direct effects on neuronal and mitochondrial functions,
astrocyte metabolism, and interference with neurotransmitters (Underwood et al., 2015; Shah
et al., 2016; Cohen et al., 2017). The ART drugs most commonly associated with depression
include efavirenz (EFV; NNRTI) and dolutegravir (DTG; INSTI) (Bengtson et al., 2017; Elzi
et al., 2017; Borghetti et al., 2017). However, little is known about the effects of most ART drugs
and ART combinations on depressive symptoms. Furthermore, ART effects may be confounded
by other factors such as sociodemographic, clinical, and behavioral characteristics. Therefore,
investigating ART effects on depressive symptoms to optimize health outcomes and facilitate
personalized medicine remains a major challenge in HIV studies.
The Women’s Interagency HIV Study (WIHS) is a large prospective, observational, longitu-
dinal, multicenter study designed to investigate the progression of HIV disease in women with
HIV or at risk for HIV infection in the United States (Bacon et al., 2005). At semiannual vis-
its, physical examinations, laboratory testing, and questionnaires regarding sociodemographics,
medication use, mental health (including depression), and self-reported clinical diagnoses are
performed and data is registered in local and national WIHS repositories. Such electronic health
records provide us unprecedented opportunities to examine the longitudinal effects of ART drugs
on depression after adjusting for socio-demographic, behavioral, and clinical factors. Figure 1(a,
b) present two womens’ ART medication history at each of their study visits (shown as calendar
dates). They were followed for different time periods with distinct visit dates and drug usages.
At each visit, participants’ depressive symptoms were also measured and recorded using the
Center for Epidemiologic Studies Depression Scale (CES-D), a 20-item self-administered ques-
tionnaire (Lewinsohn et al., 1997); see Figure 1(c, d) as an example for the same two participants.
Each question regarding depressive symptoms has an ordinal score in {0, 1, 2, 3}, with 0 being
the least severe and 3 being the most severe. The complexity of data including longitudinal
laboratory observations, heterogeneous participant population, and dynamic ART assignments,
presents analytic and modeling challenges.
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(a) Depression score for participant 1 (b) Depression score for participant 2
Figure 1: (a, b) The number of ART drugs taken by two randomly selected participants from
the WIHS versus their visit dates, respectively. Drug names are recorded and different colors
represent different drug groups. (c, d) Their depression scores of 20 questions across visits.
Prior studies examining ART-related effects on depressive symptoms in people with HIV
have used a number of self-report instruments to assess depressive symptoms including the
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15-item depression subscale of the Hopkins Symptom Checklist (D- HSCL) (Derogatis et al.,
1974), the 9-item Patient Health Questionnaire (PHQ-9) (Kroenke et al., 2001), and the CES-
D (Lewinsohn et al., 1997). However, these studies have several limitations. First, instead
of considering each individual depressive symptom, these studies use a sum-score to represent
severity, and a somewhat arbitrary threshold to distinguish individuals with depression from
healthy ones. For example, with the CES-D, people with a total score higher than 16 are
regarded as having moderate or severe depression. However, sum-score is an over-simplified
measurement for highly heterogeneous diseases like depression. Two participants with the same
score may share no common symptoms or report different symptoms being severe. Moreover, a
sum-score assumes equal contributions of all symptoms which are inconsistent with psychometric
literature (Fried et al., 2016). Therefore, lumping distinct symptoms to a single sum-score and
grouping participants with similar sum-scores but different symptoms into one category may
result in significant information loss. Second, as shown in Figure 1, data in HIV studies is often
longitudinal with changing drug assignments and depression scores over the course of treatment,
and the drug effects on depression may change over time and depend on individuals’ unique
characteristics. Existing methods only examined the cross-sectional associations between ART
drugs and depression. Therefore, there is a critical need to develop novel statistical models that
are capable of comprehensively examining non-stationary longitudinal effects of all ART drugs
on disparate depression symptoms in a heterogeneous HIV population.
To this end, we develop BAGEL, a Bayesian graphical model that can simultaneously study
personalized effects of ART drugs on item-level depression symptoms while adjusting for partic-
ipants’ longitudinal covariates, understand the participant-dependent dynamic drug effects, and
take into account the heterogeneous HIV population by clustering participants into subgroups
through a Bayesian nonparametric prior. Specifically, we use a latent bipartite graph with one
group of vertices representing ART drugs and the other group of vertices representing depressive
symptoms. The presence of an edge between a drug and a depressive symptom indicates a sig-
nificant drug-depression effect, the size of which is represented by the edge weight. Importantly,
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the effect sizes can vary across different clinical visits and different participants. Moreover,
for broader dissemination and reproducibility, the code implementing BAGEL is available at
https://github.com/YanxunXu/BAGEL.
The rest of paper is organized as follows. In Section 2 we present modeling details of BAGEL
and the posterior inference. The performance of BAGEL is evaluated through simulation studies
with comparison to alternative methods in Section 3. In Section 4, we apply BAGEL to a dataset
from WIHS to study the longitudinal ART drugs effects on depression items and demonstrate
the clinical utility of BAGEL. We conclude with a brief discussion in Section 5.
2 Model and Inference
2.1 Probability model
Let Uijq ∈ {0, 1, 2, 3} be the ordinal score of depression item q for participant i at visit j,
i = 1, . . . , n, j = 1, . . . , Ji, and q = 1, . . . , Q. In WIHS, we have Q = 20 depression items,
which measure different depressive symtoms such as “bothered by things”, “appetite was poor”,
and “fearful.” A detailed description of all 20 symptoms is provided in Section 4. A higher
score indicates a worse depressive symptom. Following Albert and Chib (1993), we introduce
a latent continuous random variable Yijq such that Uijq = k if and only if Yijq ∈ (ak, ak+1],
where k = 0, . . . , 3, a0 = −∞, and a4 = ∞. For identifiability, we set a1 = 0. Let Zijd be
a binary indicator to represent whether participant i at visit j uses drug d, d = 1, . . . , D, and
denote Zij = (Zij1, . . . , ZijD). Let Xij be an S-dimensional row vector including an intercept,
time-invariant covariates (e.g., race), and time-varying covariates (e.g., BMI, CD4 count).
We model the latent continuous depression scores Yij = (Yij1, . . . , YijQ) as follows,
Yij = Xijβi +ZijBij + ωij + ij, i = 1, . . . n, j = 1, . . . , Ji, (1)
with ij = (ij1, . . . , ijQ). The first term Xijβi captures the dependence of the latent outcome
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Yij on the covariates Xij, where βi is an S × Q matrix representing the covariate effects for
participant i. The second term ZijBij models the drug effects where Bij is a D × Q matrix
with each element Bij,dq being the contribution of drug d to depression item q for participant
i at visit j; the modeling details of drug effects Bij will be introduced later. By study design,
depression items are correlated. For example, in our data, the pairwise rank correlations of
observed depression ordinal scores range from 0.11 to 0.66. To capture such dependencies,
we assume ωij ∈ RQ follows a centered multivariate normal distribution MN(0, σ2Cω). The
sampling model is completed by assuming independent normal errors ij ∼ MN(0, σ2I), where
σ2 = 1 for identifiability.
Modeling drug-depression effects. The main contribution of the proposed model is the
formulation of the drug effects Bij, which are the key parameters of interest. Since there are
20 depression items and more than 20 drugs, to encourage parsimony, we assume Bij to be a
sparse matrix, i.e., not all drugs are associated with every depression item. Letting ◦ denote
the Hadamard product of two matrices of the same dimension, we decompose Bij = Ri ◦ Λij
multiplicatively into two components. The first componentRi = (Ri,dq) is a D×Q binary matrix
that induces sparsity in Bij with Ri,dq = 1 if drug d is significantly associated with depression
item q for participant i and Ri,dq = 0 otherwise. The matrix Ri can be also viewed as a directed
acyclic graph adjacency matrix of a bipartite network consisting of two sets of nodes: drugs
and depression items; see Figure 2 for example. The second component Λij is a D × Q matrix
that quantifies the strength of the (non-zero) drug-depression associations over time with each
element Λij,dq being the effect of drug d on depression item q for participant i at visit j. Note
that although the presence or absence of the drug-depression links Ri for participant i do not
change over time, we allow the strength of the links Λij to vary with time and covariates through
the following model,
Λij,dq = X˜ijαi,dq + s(tij), (2)
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where X˜ijαi,dq accounts for the dependence of the drug effect on participants’ covariates X˜ij,
tij denotes the time of visit j since the first visit for participant i, and s(·) is a nonlinear smooth
function. In general, X˜ij could be different fromXij but in our later simulations and application,
X˜ij = Xij.
(a)
(c)
(b)
(d)
Cluster 1
Cluster 2
Figure 2: Drug-depression relationships across visits for four participants (a)-(d) in two different
clusters. Different colors encode different visits for one participant, and the width of each edge
represents the weight of the association between the corresponding drug (circles) and depression
(squares).
We use splines to model the nonlinear function s(·) by letting s(tij) = t˜ijγi,dq, where
t˜ij = (t˜ij1, . . . , t˜ijB) denotes the cubic B-spline basis expansion of tij and B is the number
of bases. To prevent overfitting, we leverage the P-spline (Eilers and Marx, 1996) that penalizes
finite differences of adjacent B-spline coefficients to encourage smoothness. As shown in Lang
and Brezger (2004), P-splines can be written as a Bayesian hierarchical model by assuming
γi,dq ∼ MN(0, σ2γK−), where K is a singular penalty matrix constructed from the second-order
differences of the adjacent spline coefficients and K− is the pseudo-inverse of the matrix K. In
summary, the term ZijBij represents (i) the drug main effect, (ii) drug-covariate interaction,
and (iii) nonlinear drug-time interaction.
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2.2 Priors
The proposed model is parameterized by ({Θi}ni=1,Cω), where Θi = (βi,Ri, {αi,dq,γi,dq}D,Qd=1,q=1).
Although one can apply model (1) independently to one participant at a time, it is deemed
inefficient and hard to interpret, especially for individuals with few visits. We propose a joint
modeling approach through a Bayesian nonparametric (BNP) prior on Θi’s to borrow information
across participants for estimating personalized drug-depression relationships over time. We
consider a Dirichlet Process (DP) prior (Ferguson, 1974), Θi
i.i.d.∼ G and G ∼ DP (m0, G0) with a
concentration parameter m0 and a baseline measure G0(·). DP has been widely used in various
biomedical applications (Mu¨ller and Quintana, 2004; Xu et al., 2016) to account for sampling
heterogeneity. DP prior gives rise to ties of Θi’s due to its almost surely discreteness, which
elegantly defines a natural partition of participants without a pre-specified number of clusters
— i and i′ belong to the same cluster if Θi = Θi′ . Because of the presence of ties, let {Θ˜h}Hh=1
with Θ˜h = (β˜h, R˜h, {α˜h,dq, γ˜h,dq}D,Qd=1,q=1) denote the unique values of {Θi}ni=1. Let ei denote the
clustering membership indicator such that ei = h indicates participant i belongs to cluster h.
Then Θi = Θ˜h if ei = h. Given ei, the DP prior induces the following prior on Θi,
Θi =
H∑
h=1
Θ˜hI(ei = h) and Θ˜h ∼ G0.
In essence, the DP prior allows for clustering of participants by grouping participant-specific
parameters {Θi} into {Θ˜h} and makes inference for cluster-specific parameters Θ˜h using par-
ticipants within cluster h. Figure 2(a-d) illustrates the drug-depression relationships for four
participants in two different clusters with three visits recorded for participants (a) and (c) and
two visits recorded for participants (b) and (d). Participants belonging to the same cluster
share the same graph structure (encoded in Ri), although the edge weights can differ across
participants and visits (quantified by Bij). Furthermore, the BNP prior on Θi yields a flexible
nonparametric response surface for Yij capturing complex drug effect dynamics.
Let β˜hq be the q-th column of β˜h. We assume a conjugate base measure G0 of DP, G0(Θ˜h) =
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∏Q
q=1 p(β˜hq)
∏D,Q
d=1,q=1 p(R˜h,dq)p(α˜h,dq)p(γ˜h,dq) where p(β˜hq) = MN(0, σ
2
βI), p(α˜h,dq) = MN(0, σ
2
αI),
p(γ˜h,dq) = MN(0, σ
2
γK
−), and p(R˜h,dq) = Bernoulli(ρ). We consider a non-informative Unif(−1, 1)
prior for the off-diagonal elements of Cω, although alternative priors could be adopted if cer-
tain prior knowledge on the correlation structure of depression items is available. We com-
plete the model construction by assigning the following hyperpriors: σ2β ∼ inv-Gamma(aβ, bβ),
σ2α ∼ inv-Gamma(aα, bα), σ2γ ∼ inv-Gamma(aγ, bγ), and ρ ∼ Beta(αρ, βρ). The posterior in-
ference is carried out using Markov chain Monte Carlo (MCMC) simulations. Details of the
sampling procedure are described in Section A of the Supplementary Material.
3 Simulation Study
In this section, we evaluated the performance of BAGEL through simulation studies by compar-
ing posterior inference with simulation truth. Furthermore, to demonstrate the advantages of
(i) imposing a DP prior to account for participants’ heterogeneity and (ii) encouraging sparsity
in the drug-depression effects Bij, we compared BAGEL to two alternative methods. The first
method does not take into account participants’ heterogeneity by assuming that all participants
shared the same parameter, i.e., Θi = Θ and Θ ∼ G0. We call this method Homogeneous.
The second method, called NoSparsity, dropped the sparse binary matrix Ri from BAGEL, i.e.,
assuming Bij = Λij.
3.1 Simulation setup
We considered two scenarios, one with n = 200 participants and the other with n = 500 par-
ticipants. In both scenarios, we assumed that there were D = 5 drugs and Q = 3 depression
items, with the true number of clusters being H0 = 3. All participants were randomized to
the three clusters with equal probabilities. For each participant i, we generated the number of
visits Ji from a Poisson distribution with mean 10. The duration between two consecutive visits
(i.e., ti,j+1 − tij) was generated from a normal distribution with the mean 1 year and standard
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deviation 0.2. Let N(µ, σ2) denote a normal distribution with mean µ and variance σ2. For
participants’ covariates Xij, we considered two time-invariant covariates with one being gen-
erated from Bernoulli(0.5) and the other being generated from N(0, 4), and three time-variant
covariates mimicking age, body mass index (BMI), and smoking status. We randomly sampled
participants’ ages at their initial visits from the motivating WIHS dataset with replacement,
then computed their ages at followup visits based on the generated tij’s. The BMI and smoking
status were generated from N(28, 8) and Bernoulli(0.6) independently across participants and
their visits, respectively. The drug usage Zijd for participant i at visit j was generated from
Bernoulli(0.8) independently.
Conditional on clustering memberships, the simulated true values of βi’s and αi’s in both sce-
narios are tabulated in Supplementary Tables T1 and T2. For the matrixRi that induces sparsity
in drug-depression effects, we generated each element Ri,dq independently from Bernoulli(0.4).
The simulated true s(tij) was assumed to be s(tij) = 6tij. Setting Cω to be

1 0.3 0.35
0.3 1 0.4
0.35 0.4 1

and the threshold to be (a1, a2, a3) = (0, 8, 16), we generated the latent continuous Yijq from (1) as
well as the corresponding ordinal depression scores Uijq, i = 1, . . . , n; j = 1, . . . , Ji; q = 1, . . . , Q.
We applied BAGEL to the simulated dataset with 100 repeated simulations in both scenarios.
The hyperparameters were set to be m0 = 1, aβ = aα = aγ = 3, bβ = bα = bγ = 10, αρ =
1, and βρ = 10. In each analysis, we ran 20,000 MCMC iterations with an initial burn-in of
10,000 iterations, thinned by 10. We assessed the convergence using R package coda, showing
no sign of lack of convergence.
3.2 Simulation results
We first evaluated the clustering performance of BAGEL. BAGEL successfully identified Hˆ = 3
clusters in both scenarios, since the marginal posterior probabilities of the simulated true number
of clusters averaged over 100 repeated simulations were p(H = 3 | data) = 99.6% when n = 200,
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and p(H = 3 | data) = 89.1% when n = 500. We calculated the posterior co-clustering
probabilities of participants based on the empirical proportion of participants being clustered
together over the post-burn-in MCMC samples. The simulated true clustering schemes and the
co-clustering probability matrices for one randomly selected simulation under both scenarios
are depicted in Supplementary Figure F1, showing that BAGEL assigns participants to their
simulated true clusters with high probabilities.
Reporting cluster-specific parameters is challenging due to the issue of label switching. Fol-
lowing Dahl (2006), let ei denote the clustering membership indicator of participant i and V be
an n× n matrix whose entry Vi1,i2 = P(ei1 = ei2) represents the posterior probability of partici-
pants i1 and i2 being clustered together, which can be computed based on posterior samples. In
each MCMC iteration, we computed an n×n binary matrix Ve, whose entry V ei1,i2 = I(ei1 = ei2)
indicates whether participants i1 and i2 are clustered together at that iteration. The clustering
that minimizes the Frobenius distance between Ve and V, given by eˆ = arg mine‖Ve −V‖, is
called the least-square summary of clustering. Then we relabeled the cluster memberships at
each MCMC iteration by minimizing its Frobenius distance to the least-square summary as a
post-processing step (Li et al., 2019). Supplementary Figures F2 and F3 plot posterior means
and 95% credible intervals (CIs) for β˜hq’s and α˜h,dq’s averaged over 100 repeated simulations,
respectively, showing that all 95% CIs are centered around the simulated true values. To as-
sess the ability of BAGEL in recovering the sparsity Ri of drug effects, we plotted the posterior
probabilities of R˜h,dq being equal to the simulated true values in Supplementary Figure F4 under
both scenarios, indicating satisfactory performance. We also computed the true positive rates
(TPR) and false discovery rates (FDR) for recovering Ri under both scenarios: when n = 200,
TPR=0.96, FDR=0.08; when n = 500, TPR=0.98, FDR=0.02, indicating good recovery.
Next, we examine whether BAGEL can recover individualized longitudinal drug effects Bij,
j = 1, . . . , Ji. We randomly selected one participant from each of the three clusters in one
simulated dataset when n = 200. These participants had 14, 7, and 8 visits, respectively.
As drug effects for one participant are different across different drugs and depression items,
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we computed the posterior summaries of Bij,dq for the randomly selected d and q such that
Ri,dq 6= 0 for illustration (note that when Ri,dq = 0, the corresponding Bij,dq = 0). Figure 3 plots
the estimated posterior means of Bij,dq’s with 95% CIs for these three participants, indicating
that BAGEL can successfully recover the simulated true drug effects.
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Figure 3: Simulated true values, posterior means with 95% CIs of the estimated Bij,dq under
BAGEL, and posterior means under two alternative methods: NoSparsity and Homogeneous for
three participants randomly selected from each of the three clusters, respectively. The black dots
represent simulation truths; the green dots represent posterior estimates under BAGEL; the blue
and pink dots represent posterior estimates under NoSparsity and Homogeneous, respectively.
Furthermore, we compared BAGEL with two alternative methods: Homogeneous and NoSpar-
sity. Figure 3 shows the estimated posterior means of Bij,dq under the two alternatives. Both
BAGEL and NoSparsity estimated the drug effects much better than the Homogeneous method,
especially for participants from clusters 1 and 2 partly because the drug effects may be averaged
out in a heterogeneous population and hence greatly biased towards zero. BAGEL slightly out-
performed NoSparsity with substantially better interpretability due to sparsity. In addition, as
shown in Supplementary Figures F5 and F6, the CIs for the model parameters of NoSparsity tend
to be wider than those of BAGEL. We also compared the three methods in terms of Watanabe-
Akaike information criterion (WAIC) (Watanabe, 2010; Gelman et al., 2014). BAGEL yielded
the smallest WAIC, which was 3688.73, while the WAIC values of NoSparsity and Homogeneous
were 3816.89 and 9602.72, respectively.
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4 The WIHS Data Analysis
4.1 Data
The WIHS is a multi-center, longitudinal study developed to characterize the natural and treated
history of HIV infection and clinical outcomes in women residing in the United States (Barkan
et al., 1998; Bacon et al., 2005; Adimora et al., 2018). WIHS participants complete “core” visits
approximately every 6 months. At each visit, women undergo clinical examination, structured
medical and psychosocial interviews, and laboratory testing to assess HIV status/viral load. For
the present analysis, we included all visits after January 2012 from women in the Washington,
D.C. WIHS site resulting in a total of 214 participants with 1,240 visits. The primary outcome
of interest was the item-level responses on CES-D, a 20-item self-administered questionnaire,
which is commonly used to assess depression in HIV studies (Moore et al., 1999; Ickovics et al.,
2001; Maki et al., 2012). The CES-D measures the frequency of depressive symptoms (e.g.,
“people dislike me”) during the week prior to the visit, where “0” indicates no symptom or the
duration of symptom is less than one day, “1” indicates the duration of symptom is between
one and two days, “2” indicates the duration of symptom is between three and four days, and
“3” indicates the duration of symptom is longer than five days. Figure 5 lists all 20 symptoms,
which can be categorized in three types: somatic, affect, and interpersonal symptoms. Somatic
symptoms include unpleasant or worrisome mood such as “restless”, “appetite”, and “concen-
tration.” Affect symptoms include the lack of positive affect (e.g., “enjoyed life”, “hopeful of
future”) and/or the presence of negative affect (“fearful”, “lonely”, “failure”). Interpersonal
symptoms include“people disliked me” and “people unfriendly”. The items reflecting positive
affect were reversed scored so that higher values on each item reflected more negative symptoms.
We included the following sociodemographic, behavioral, and clinical covariates as risk factors
(Cook et al., 2002; Rubin et al., 2011; Maki et al., 2012) for depressive symptoms: age, body mass
index (BMI), CD4 count, nadir CD4 count (CD4 Nadir), viral load (VLOAD), race, smoking,
substance abuse (e.g., marijuana, cocaine, and heroin), and education. Table 1 summarizes these
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characteristics of participants at their first visits in the dataset. There were 23 drugs used in the
dataset, falling into five drug classes: NRTI, NNRTI, PI, EI, and INSTI. The drug use frequency
varies significantly among different drugs from hundreds of visits to only few visits, the details
of which are reported in Supplementary Table T3.
4.2 Results
We applied BAGEL to the dataset with the same hyperparameters as in the simulation study.
The least-square summary of clustering estimated four clusters with the number of participants
in each cluster being 94, 105, 6, 9, respectively. Table 1 summarizes demographic, clinical, and
behavioral characteristics of participants in the four clusters at their first visits, and Supplemen-
tary Table T3 reports the frequency of the ART drugs used in the four clusters. Since clusters
3 and 4 only had few participants, our subsequent analyses and clinical interpretation focused
on clusters 1 and 2.
Figure 4 plots posterior means and the corresponding 95% CIs of the estimated effect sizes of
age, CD4, viral load, and smoking for four randomly selected depressive symptoms: “appetite”,
“bothered”, “crying spells”, and “talked less.” As shown in Figure 4, covariates have distinct
effects in different clusters on different depression items. Panel (a) shows that younger people
had less lack of appetite in both clusters 1 and 2, but 95% CIs covered 0, indicating that the age
effects were not significant on appetite in both clusters. In contrast, the effect of age on “crying
spells” was significant in cluster 2, but not in cluster 1, highlighting the heterogeneity among
participants. Panel (b) indicates that a higher CD4 was associated with less “crying spells” in
cluster 2. Panels (c) and (d) show that a higher viral load and smoking were associated with
more lack of appetite in cluster 1, but not in cluster 2. As shown in Table 1, the proportion
of smoking participants in cluster 1 (52%) is significantly higher than that in cluster 2 (22%),
indicating that women who smoke are more likely to experience lack of appetite when viral load
is high. These findings are consistent with the literature (Brink et al., 2010; Taniguchi et al.,
2014; Clubreth et al., 2016; Williams et al., 2020).
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Overall Cluster
(n=199) 1 (n=94) 2 (n=105) 3 (n=6) 4 (n=9)
Variables n(%) n(%) n(%) n(%) n(%)
Demographics
Age (years)
≤ 35 10 (5) 4 (4) 6 (6) 0 (0) 0 (0)
36-45 66 (33) 28 (30) 38 (36) 3 (50) 5 (56)
46-55 80 (40) 40 (43) 40 (38) 2 (33) 3 (33)
> 55 43 (22) 22 (23) 21 (20) 1 (17) 1 (11)
BMI
< 18.5 6 (3) 3 (3) 3 (3) 0 (0) 0 (0)
18.5-29.9 107 (54) 50 (53) 57 (54) 5 (83) 4 (44)
30-39.9 59 (30) 25 (27) 34 (32) 1 (17) 4 (44)
≥ 40 27 (13) 16 (17) 11 (11) 0 (0) 1 (12)
Race
White 35 (18) 12 (13) 24 (23) 0 (0) 0 (0)
Black 150 (75) 76 (81) 74 (70) 6 (100) 8 (89)
Others 13 (7) 6 (6) 7 (7) 0 (0) 1 (11)
HIV-related clinical characteristics
CD4
≤ 250 18 (9) 10 (11) 8 (8) 1 (17) 0 (0)
251-500 57 (29) 32 (34) 25 (24) 2 (33) 3 (33)
501-1000 107 (54) 44 (47) 63 (60) 3 (50) 6 (67)
≥ 1001 17 (8) 8 (8) 9 (8) 0 (0) 0 (0)
CD4NADIR
≤ 250 74 (37) 31 (33) 43 (41) 2 (33) 3 (33)
251-500 98 (49) 48 (51) 50 (48) 4 (67) 4 (45)
> 500 27 (14) 15 (16) 12 (11) 0 (0) 2 (22)
VLOAD
≤ 500 168 (85) 81 (87) 87 (83) 5 (83) 8 (89)
501-5000 14 (7) 6 (6) 8 (8) 0 (0) 1 (11)
5001-50000 15 (7) 6 (6) 9 (8) 1 (17) 0 (0)
> 50001 2 (1) 1 (1) 1 (1) 0 (0) 0 (0)
Lifestyle
Smoking
Yes 72 (36) 49 (52) 23 (22) 2 (33) 3 (33)
No 127 (64) 45 (48) 78 (78) 4 (67) 6 (67)
Substance abuse
Yes 24 (12) 15 (16) 9 (9) 0 (0) 1 (11)
No 175 (88) 79 (84) 96 (91) 6 (100) 8 (89)
Education
<High school 49 (25) 23 (24) 26 (25) 0 (0) 1 (11)
High school 121 (61) 62 (66) 59 (56) 5 (83) 8 (89)
≥College 29 (14) 9 (10) 20 (19) 1 (17) 0 (0)
Table 1: Demographic, clinical, and behavioral characteristics of participants at their first visits
in the overall sample and in the four clusters.
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Figure 4: Posterior means and 95% CIs for the estimated coefficients corresponding to age, CD4,
viral load, and smoking. The dots represent the posterior means.
Then we report the estimated R˜h,dq, which represents if drug d is significantly associated with
depression item q for participants in cluster h. Note that R˜h,dq only indicates whether the signif-
icant association exists. The sign and magnitude are represented by Bij through Λij, which will
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be summarized later. Figure 5 presents the associations between ART drugs and 20 depression
items in clusters 1 and 2 corresponding to the least-square point estimate, showing that the
drug-depression associations are different between clusters. Supplementary Figure F7 plots the
posterior probabilities of {R˜h,dq = 1} across all drugs and depression items. The most frequently
used NRTI in the dataset, TDF, was associated with the symptom “people unfriendly” in cluster
1, and “restless” and “effort” in cluster 2. Several clinical trials have reported the associations
between TDF and depression (Squires et al., 2003; Mills et al., 2016). The most frequently
used NNRTI drug, EFV, was associated with nearly half of the depression items in cluster 1 and
three items in cluster 2. This is consistent with studies demonstrating associations between EFV
and depressive symptoms, such as suicidal behavior (Mollan et al., 2014; Bengtson et al., 2017;
Arenas-Pinto et al., 2018). INSTI drugs have also been linked to psychiatric symptoms including
depression and are among primary reasons for discontinuing INSTI treatment (Hoffmann et al.,
2017; Borghetti et al., 2018; Revuelta-Herrero et al., 2018). For example, Harris et al. (2008)
reported several treatment-experienced HIV-seropositive patients had significant exacerbation
of pre-existing depression after starting to take RAL, an INSTI drug. The proposed BAGEL
identified significant associations between two of the INSTI drugs (EVG and RAL) and several
depression items in the two clusters. Compared to previous studies, BAGEL not only deter-
mines whether a certain drug is significantly associated with depression, but also which specific
depression item that drug is associated with. Since two people with the same sum-score (total
depression score) may have distinct symptoms that have different consequences and require dif-
ferent treatments, these more precise findings demonstrate the potential of BAGEL to facilitate
precision medicine on treating HIV and its comorbidities including depression.
Next we report the estimation of drug effects Bij on depressive symptoms for participant i
at visit j. For illustration, we randomly selected one participant from each of clusters 1 and
2, called participant 1 and participant 2 hereafter. Figure 6 depicts the associations between
ART drugs and item-level depressive symptoms over time for participant 1. Blue lines indicate
that the ART drug is associated with less symptomatology, indicating favorable effects in re-
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Figure 5: Associations between ART drugs and depression items: a color-filled cell indicates
that there exists significant association between the corresponding drug and depression item.
ducing depressive symptoms, and red lines indicate that the ART drug is associated with more
symptomatology, indicating unfavorable effects on symptoms. The width of the line is propor-
tional to the magnitude of the association. The drug effects on depressive symptoms change
over time, in both magnitude and sign. Particularly, participant 1 had 5 visits and used two
NRTIs (TDF+FTC) and one NNRTI (NVP) in all 5 visits. TDF was associated with more
symptomatology on “restless”, and the negative effect was magnified over time: 0.055 at the
first visit, then 0.211, 0.309, 0.47 at visits 2-4, until 0.693 at the last visit, indicating that the
long-term use of TDF could cause lasting and worse sleeping issue for people with HIV. TDF
was associated with less symptomatology on “effort” at the first visit with the corresponding
Bij,dq being -1.472, but the beneficial effect kept decreasing at the second and third visits with
effects being -0.795 and -0.379, respectively. At the fourth visit, the beneficial effect of TDF
on “effort” became harmful with the effect being 0.013, then became worse at the fifth visit
with the effect being 0.941. In contrast, FTC had beneficial effect on “effort”, and the effect
kept increasing over time. NVP was also beneficial for “energy” in all visits. In general, failure
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to suppress viral load and severe side effects are two major reasons for treatment switch. This
participant’s viral loads were undetectable in all five visits and she was consistently reported use
of TDF+FTC+NVP, which agreed with our finding that TDF+FTC+NVP was well tolerated
in terms of depressive symptoms. However, if sleeping problem was the major concern for this
woman, and such symptom might not be reflected by the CESD sum-score since the overall score
could be dominated by positive effects of drugs on other symptoms, then BAGEL could guide
the physician to switch treatment by considering another NRTI to replace TDF.
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Figure 6: Drug effect on depression symptoms for participant 1. Blue lines indicate that the
ART drug is associated with less symptomatology and red lines indicate that the ART drug is
associated with more symptomatology. The width of the line indicates the magnitude of the
association.
Figure 7 plots the associations between ART drugs and item-level depressive symptoms over
time for participant 2. This participant had three visits: at the first two visits, she reported using
two NRTIs (TDF and FTC) and one INSTI (EVG); at her last visit, she reported using the same
two NRTIs but switched to another INSTI (RAL). Since RAL is not significantly associated with
any depressive symptom in cluster 2, there is no edge connecting RAL with symptoms. TDF was
associated with less symptomatology in two somatic symptoms (“restless” and “effort”) at her
first visit, then the beneficial effects decreased at her second visit. As she continued to take TDF,
20
the effects of TDF turned negative on these two depressive symptoms at her last visit. TDF
was reported to have limited neurotoxic effects due to its low central nervous system penetrance
(Best et al., 2012). However, our finding highlights the need of evaluating the long-term effect
of TDF on depressive symptoms in people with HIV, especially somatic symptoms. EVG had a
positive effect on “effort” and a negative effect on “hopeful of future” at her first visit, then the
effect on “effort” became negative at her second visit. Previous clinical trials (Cohen et al., 2011;
Abers et al., 2014) reported psychiatric adverse events for participants treated with EVG. As
shown in Figure 7, this participant switched from EVG to RAL, indicating that those negative
effects of EVG on depression may be the major reason for this switch because her viral loads
were well suppressed across all visits and hence unlikely caused the switch.
Lastly, we demonstrate how BAGEL can guide more informed and effective individualized
ART drug selection for better depression control in HIV clinical practice. Assume that we have
observed data for participant i at her first Ji visits, denoted by Di = {Uijq,Zij}Q,Jiq=1,j=1, and we
aim to find an optimal drug combination at her (Ji + 1)-st visit. For example, pretending that
participant 2 has data reported up to her second visit, i.e., Ji = 2, the analysis with BAGEL
can assist physician in drug management at her third visit. The US department of Health and
Human Service has recommended two NRTI drugs as backbone with an additional INSTI drug
as first-line therapy (https://aidsinfo.nih.gov/guidelines). Assume that at her third visit, the
physician wants to choose two NRTIs from TDF, 3TC, and FTC, and choose one INSTI from
RAL, EVG, and DTG, resulting in a total of 9 possible combinations. Denote the posterior
predictive probability of the q-th depression score at her third visit being larger than 0 under
drug combination z by piiq(z) = Pr(Ui3q > 0 | Zi3 = z,Di), q = 1, . . . , Q which is shown
in Figure 8. As an example, we define an individualized utility score ∆i(z) as the criteria of
choosing an optimal drug combination based on the sum of posterior predictive probabilities for
all depression items ∆i(z) =
∑
q piiq(z). Clearly, a drug combination is less desirable if it has
a higher score. For simplicity, we first compare two candidate drug combinations that she took
at her first two visits (Figure 7), z1=TDF+FTC+EVG and z2=TDF+FTC+RAL. We found
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Figure 7: Drug effect on depression symptoms for participant 2. Blue lines indicate that the
ART drug is associated with less symptomatology and red lines indicate that the ART drug is
associated with more symptomatology. The width of the line indicates the magnitude of the
association.
∆i(z1) = 2.988 with the top three adverse effects being “effort” (0.439), “talked less” (0.290),
and “concentration” (0.188) whereas ∆i(z2) = 2.714 with the top three adverse effects being
“effort” (0.307), “restless” (0.210), and “happy” (0.202). Since z2=TDF+FTC+RAL leads to a
smaller utility score, we claim that z2=TDF+FTC+RAL is better than z1=TDF+FTC+EVG in
controlling overall depressive symptoms for this participant and hence would recommend a drug
switch from EVG to RAL at her third visit. As shown in Figure 7, the physician’s actual choice
was indeed RAL, which agreed with our prediction. However, if DTG was considered in the
comparison, we would recommend the drug combination TDF+TFC+DTG since it is expected
to cause the least depressive symptomatology: ∆i(z) = 2.646 with the top three adverse effects
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being “effort” (0.261), “restless” (0.224), and “concentration” (0.215).
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Figure 8: Posterior predictive probabilities of depression items at participant 2’s third visit given
the data from her first two visits and various combinations of ART drugs. TDF+TFC+DTG is
the optimal drug combination based on the utility score since it leads to the smallest ∆(z).
Note that in our simple illustrative example, the defined individualized utility score ∆i(z)
simply sums over all depression items with equal weights. In clinical practice, different cate-
gories of depression symptoms might impact clinical utility differently. For example, somatic
symptoms including “energy”, “talked less”, “restless”, “effort”, “concentration”, “appetite”,
and “bothered”, have been shown more likely to cause discontinuation of treatment for people
with HIV (Kapfhammer, 2006; Taibi, 2013). Therefore, the utility score ∆i(z) can be adjusted
to impose more weights on somatic symptoms chosen according to the physician’s opinion or in-
dividual preference of people with HIV. For example, let Ξ denote the set of somatic symptoms,
the utility score can be alternatively defined as ∆˜i(z) =
∑
q∈Ξ piiq(z) if the physician wants to
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focus on somatic symptoms. Again, take participant 2 for illustration. We computed ∆˜i(z)
for all 9 drug combinations and concluded that TDF+FTC+DTG was still the optimal choice.
Finally, we remark that the flexibility of choosing utility score is enabled by one of the prominent
features of BAGEL, i.e., precise probabilistic characterization of ART drug effects on item-level
depressive symptoms.
5 Conclusion
To better understand the long-term effects of ART or ART drug switches on item-level de-
pressive symptoms longitudinally and facilitate HIV precision medicine, we developed BAGEL,
a novel Bayesian graphical model that estimates longitudinal drug effects on depression while
accounting for participants’ heterogeneity as well as demographic, clinical, and behavior charac-
teristics. Through simulation studies and analysis of the WIHS dataset, we have demonstrated
that BAGEL accurately estimates the longitudinal drug effects, yields meaningful and inter-
pretable results, and has the potential to assist physicians’ decisions on personalized ART drug
prescriptions. In addition, we have made the code that implements BAGEL publicly available
so that users can apply BAGEL to datasets in a similar setup.
We focus on the effects of ART drugs on depressive symptomatology in this paper, but
BAGEL is also helpful to understand other ART-related complications such as cognitive impair-
ment using the model of Yij directly since cognition outcomes are continuous. BAGEL can also
be easily extended to incorporate genetic polymorphisms, an important factor in studies related
to mental health and HIV as the use of certain ART drugs in the setting of specific genetic poly-
morphisms can increase risk for adverse effects on mental health. For example, EFV combined
with polymorphisms in CYP2B6 and CYP2A6 increases the risk of suicidality (Bengtson et al.,
2017; Mollan et al., 2017). DTG combined with polymorphisms in SLC22A2 is associated with
psychiatric symptoms (Borghetti et al., 2018). In the proposed model, polymorphisms can be
incorporated as time-invariant covariates, i.e., being part of Xij. With this setup, we inlcude
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the main effects of polymorphisms (via Xijβi) as well as their interactions with ART drugs (via
ZijBij).
BAGEL is based on a longitudinal directed acyclic graphical model. Although specifically
motivated by the WIHS application, it can be applied to other biomedical longitudinal studies
or to other fields. For example, in sports medicine, individual monitoring of stress and recovery
provides useful information to prevent injuries and illnesses in athletes, and a number of longi-
tudinal studies have been conducted in sports such as soccer and basketball (Jones et al., 2017).
BAGEL can be applied to such longitudinal datasets to study the impact of psychosocial stress
on the risk of sports injuries adjusting for physical stress effect.
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